Nasdaq huma.

Insiders have purchased a total of 51,525 HUMA shares in the last 24 months for a total of $192,428.00 bought. Which Humacyte insiders have been selling company stock? The following insiders have sold HUMA shares in the last 24 months: Brady W Dougan ($11,315,945.21), Heather Ledbetter Prichard ($36,817.79), and Laura E …DURHAM, N.C., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at ...WebHUMA Earnings Date and Information. Humacyte last posted its earnings results on August 14th, 2023. The reported ($0.22) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.22). Humacyte has generated ($0.87) earnings per share over the last year ( ($0.87) diluted earnings per share).Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and complex tissue and organ systems designed to ...

Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and complex tissue and organ systems designed to ...Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems ...Humacyte, Inc. (HUMA) NasdaqGS - NasdaqGS Real Time Price. Currency in USD. Follow. 2W 10W 9M. 2.6600 +0.0100 (+0.38%) At close: 04:00PM EST. 2.7500 +0.09 (+3.38%) After hours: 05:59PM EST.

Some Humacyte, Inc. (NASDAQ:HUMA) shareholders may be a little concerned to see that the Director, Brady Dougan, recently sold a substantial US$2.7m worth of stock at a price of US$9.10 per share.

Find the latest Financials data for Humacyte, Inc. Common Stock (HUMA) at Nasdaq.com.Jan 4, 2022 · DURHAM, N.C., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced the first preclinical results of the use of Humacyte’s Human Acellular Vessel™ (HAV) in coronary artery bypass ... Humacyte, Inc. (NASDAQ:HUMA) Q4 2022 Earnings Call Transcript March 27, 2023 Operator: Good morning, ladies and gentlemen, and welcome to the Humacyte Fourth Quarter and Year-End 2022 Results ...DURHAM, N.C., April 04, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at ...Web

Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and complex tissue and organ systems designed to ...

23.12%. Get the latest Humacyte Inc (HUMA) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.

Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems ...Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients ...Humacyte, Inc. (NASDAQ:HUMA) Q3 2023 Earnings Call Transcript November 10, 2023 Operator: Good afternoon, ladies and gentlemen, and welcome to the Humacyte Third Quarter Results Conference Call.According to the issued ratings of 3 analysts in the last year, the consensus rating for Humacyte stock is Moderate Buy based on the current 1 hold rating and 2 buy ratings for HUMA. The average twelve-month price prediction for Humacyte is $7.75 with a high price target of $16.00 and a low price target of $3.00.DURHAM, N.C., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at ...Biotech firm Humacyte, Inc. (NASDAQ:HUMA) became a public company last year by merging with Alpha Healthcare Acquisition Corp., a SPAC, in a deal that valued the former at $1.1 billion.Web

$467.50 +8.50 +1.85% Find the latest SEC Filings data for Humacyte, Inc. Common Stock (HUMA) at Nasdaq.com.Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems ...HUMA Earnings Date and Information. Humacyte last posted its earnings results on August 14th, 2023. The reported ($0.22) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.22). Humacyte has generated ($0.87) earnings per share over the last year ( ($0.87) diluted earnings per share).HAV granted second RMAT designation by the FDA RMAT will support Humacyte’s lead indication in Vascular Trauma. DURHAM, N.C., May 04, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a ...WebWebsite. 2004. 164. Laura Niklason. https://www.humacyte.com. Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific ...14 Aug 2023 ... It's basically an implantable chunk of vascular conduit, which has already been shown to work in testing in Ukraine. Humacyte was using its HAV ...Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems ...

Humacyte Stock Price, News & Analysis (NASDAQ:HUMA) $2.71 +0.03 (+1.12%) (As of 12:02 PM ET) Compare Today's Range $2.66 $2.77 50-Day Range …

Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems ...Webull offers HUMA Ent Holdg (HUMA) historical stock prices, in-depth market analysis, NASDAQ: HUMA real-time stock quote data, in-depth charts, free HUMA options chain data, and a fully built financial calendar to help you invest smart.Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems ...Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients ...Dec 4, 2023 · HUMA Earnings Date and Information. Humacyte last posted its earnings results on August 14th, 2023. The reported ($0.22) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.22). Humacyte has generated ($0.87) earnings per share over the last year ( ($0.87) diluted earnings per share). DURHAM, N.C., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at ...WebHumacyte, Inc. Common Stock (HUMA) After-Hours Stock Quotes - Nasdaq offers after-hours quotes and extended trading activity data for US and global markets. Humacyte, Inc. (NASDAQ:HUMA) Q4 2022 Earnings Call Transcript March 27, 2023 Operator: Good morning, ladies and gentlemen, and welcome to the Humacyte Fourth Quarter and Year-End 2022 Results ...Back to HUMA Overview. Get up to 10 years of daily historical stock prices & volumes. The "Close/Last" is the “adjust consolidated close price”. Data provided by Edgar Online . The net and ... Humacyte First Quarter 2022 Financial Results and Corporate Update Conference Call and Webcast. Date: Friday, May 13, 2022. Time: 8:00 a.m. ET. Conference Call Details: Toll-Free: 1-877-704-4453 ...Web

3 Wall Street research analysts have issued twelve-month target prices for Humacyte's stock. Their HUMA share price targets range from $3.00 to $16.00. On average, they expect the company's stock price to reach $7.75 in the next twelve months. This suggests a possible upside of 189.2% from the stock's current price.

Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems ...

Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients ...ea50f7c1559082d0.T63vstHMEXsO6k9Xo3qg0Ymu6W5EunGNDY9lMNQE-DI.eezW-pD9UxZM3joTyhPngebCrSkO2znYfOstaaxMgkAmxLftpIB_LlyCIA Advanced …Joshua Franklin Reuters. Published. Feb 17, 2021 06:56PM EST. Humacyte Inc, a developer of universally implantable bioengineered human tissues and organs, said on Wednesday it has agreed to a deal ...Humacyte, Inc. HUMA, HUMAW on Nasdaq. This company's Exchange Act registration has been revoked. This company's Exchange Act registration as a Municipal ...Nov 29, 2023 · According to 3 analysts, the average rating for HUMA stock is "Buy." The 12-month stock price forecast is $8.67, which is an increase of 223.51% from the latest price. Net loss was $3.7 million for the fourth quarter of 2022, compared to net income of $42.6 million for the fourth quarter of 2021, and net loss was $12.0 million for the year ended December 31 ...Some Humacyte, Inc. (NASDAQ:HUMA) shareholders may be a little concerned to see that the Director, Brady Dougan, recently sold a substantial US$2.7m worth of stock at a price of US$9.10 per share.Humacyte, Inc. HUMA, HUMAW on Nasdaq. This company's Exchange Act registration has been revoked. This company's Exchange Act registration as a Municipal ...DURHAM, N.C., March 21, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at ...Web

Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients ...Humacyte Stock Price, News & Analysis (NASDAQ:HUMA) $2.71 +0.03 (+1.12%) (As of 12:02 PM ET) Compare Today's Range $2.66 $2.77 50-Day Range …DURHAM, N.C., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue ...WebInstagram:https://instagram. buy sell hold stock analysisreit passive income calculatormicrosoft optionsregulated offshore forex brokers Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients ...Web define intraday tradingwebsite for day trading financials. Financial Summary · Income Statement · Balance Sheet · Cash Flow. Humacyte Inc (HUMA). Humacyte Inc (HUMA). 2.66 +0.01 (+0.38%) 12/01/23 [NASDAQ]. stock price abb Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and complex tissue and organ systems designed to ...Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and complex tissue and organ systems designed to ...